SecBot SecBot
8-K ·Filed Nov 9, 2026

FTH

Faeth Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7d 14h ago SEC0001193125-26-452643
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The 33% ORR and 7.4-month mPFS compare favorably to the 3-4 months typical for salvage chemotherapy alone, per management. Watch for regulatory alignment discussions and Phase 3 trial design details. The stock's 10.4% normal daily move means a 6 impact score implies a move of roughly 1.5-2.5 standard deviations.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$12.68
T+0 close · Nov 9, 2026 · via day close
Latest settled
−26.81%
T+5 · $9.28
Vs SPY
−25.12%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $12.68entry
  2. T+1 · 7d ago +1.89%α +2.26% · $12.92
  3. T+5 · 15h ago −26.81%α −25.12% · $9.28
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Faeth Therapeutics announced positive preliminary Phase 2 topline results for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer. The trial met its primary endpoint with a 33% confirmed ORR and 7.4-month median PFS in a heavily pretreated population. The company plans to advance to a Phase 3 registrational trial, subject to regulatory alignment.

Key Facts

  • Confirmed ORR of 33% (12 of 36 efficacy-evaluable patients) in advanced endometrioid endometrial cancer
  • Among PIK3CA-mutation patients, confirmed ORR was 44% (7 of 16)
  • Preliminary median PFS of 7.4 months (95% CI 5.3-NR) and 6-month PFS rate of 62%
  • Disease control rate (DCR) of 83% (30 of 36)
  • 5% discontinuation rate due to treatment-related adverse events; no treatment-related deaths
  • Company plans to advance PIKTOR into a Phase 3 registrational trial
  • Trial conducted in collaboration with GOG Foundation (GOG-3111)

Financial Impact

No financial figures disclosed; clinical data supports potential regulatory path for lead asset PIKTOR

Risk Factors

  • Data are preliminary from a single-arm Phase 2 trial; results may change with further follow-up
  • PIKTOR is investigational and not yet approved by any regulatory authority
  • 64% of patients had grade 3 or higher treatment-related adverse events, notably neutropenia (26% grade 3+)
  • Phase 3 trial design and regulatory alignment are not yet finalized
  • Company may need additional financing to fund Phase 3 development

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452643
Document: d199028d8k.htm0001193125-26-452643
Document: 0001193125-26-452643-index-headers.html0001193125-26-452643
Document: 0001193125-26-452643-index.html0001193125-26-452643
Document: 0001193125-26-452643.txt0001193125-26-452643

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026